GLIB.A is a stock where shorts have been decisively wrong for weeks — and the data shows them quietly unwinding.
The short interest story here is the headline. Bears have cut their exposure sharply: SI has fallen 27% over the past month, dropping from roughly 517,000 shares in mid-July to 378,000 now, bringing short interest to 10.4% of the free float. That remains an elevated absolute level, but the direction is unambiguous. In a single week, short interest fell 10.8%. The stock, meanwhile, has rallied 20% in a month and 6% in the past week alone, closing at $26.52 on Tuesday. Shorts caught on the wrong side of that move have had little choice but to reduce.
The lending market tells a notably relaxed story, which makes the short retreat look more like a deliberate tactical exit than a forced squeeze. Availability is running at approximately 398% — meaning there are roughly four shares available to borrow for every one currently lent out. That is comfortably within normal territory, and a long way from the 52-week peak utilization of 41.7%. Cost to borrow has nudged up 24% on the week to 1.30%, but in absolute terms that is still cheap — well under 2% annualized — so bears facing margin pressure from elevated borrow costs are not the story here. The ORTEX short score has also eased from 59.3 to 57.4 over the past ten days, tracking the reduction in short positioning. On the factor ranking leaderboard, short score sits in the 11th percentile — meaning this stock ranks as one of the less squeeze-pressured names in the universe despite an ostensibly high headline SI number.
The Street angle provides some context for why shorts may have been building positions in the first place. The most recent analyst consensus data is stale — the available price target mean of $54 dates from May 2026 and should be treated with caution rather than as a live read. What the factor scores do capture is a stock where the fundamental case remains mixed. EPS surprise ranks in the 20th percentile, dividend score is also 20th, and analyst recommendation differential sits near the middle of the pack at 48th. The ORTEX stock score note from late July flagged persistent momentum underperformance, with relative strength readings deeply negative across medium-term windows — though the month's 20% rally has clearly started to repair some of that technical damage.
Ownership is where the most interesting structural dynamic lies. John Malone — as Chairman and largest named holder — controls 8.6% of shares, with his reported position last updated in mid-August showing a 529,000-share addition. That filing adds a meaningful fundamental floor to the story: the stock's largest insider is actively adding, not trimming. Institutional backing is broad, with BlackRock at 7.4%, two Vanguard entities together near 10%, and active managers including Dimensional, American Century, and State Street all present. Insider trade data is stale (last confirmed activity November 2025), so no fresh signal is available from that channel this week.
Among peers, CMCSA gained 2.1% on the week while LILA slipped 2.2% and CCOI fell 6.4% — making GLIB.A's 6% weekly gain the standout in its peer group. The divergence suggests stock-specific buying rather than a sector tailwind lifting all boats.
The next earnings event is logged for November 6. Between now and then, the key dynamic to watch is whether the remaining 10.4% short interest continues its controlled retreat — or whether the stock's recent momentum starts to accelerate that exit.
See the live data behind this article on ORTEX.
Open GLIB.A on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
